3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Pain
3
Neoplasms
3
Gastrointestinal Neoplasms
2
Depression
2
Anxiety Disorders
2
Peripheral Nervous System Diseases
1
Pain, Postoperative
1
Otolaryngeal Cancer
1
Neurotoxicity Syndromes
1
Mucositis
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Cancer Pain
1
Breast Neoplasms
1
Agnosia
1
Acute Pain
1
Interventions
Surveys and Questionnaires
2
Analgesics, Opioid
2
trimebutine 3-thiocarbamoylbenzenesulfonate
1
acetaminophen, aspirin, caffeine drug combination
1
Uterine Myomectomy
1
Transcutaneous Electric Nerve Stimulation
1
Therapeutics
1
Tea
1
Tapentadol
1
Saline Solution
1
Ropivacaine
1
Propofol
1
Nerve Block
1
Meperidine
1
Lidocaine
1
Ketamine
1
Injections, Subcutaneous
1
Fentanyl
1
Anesthetics, Local
1
Anesthesia, Local
1
Anesthesia, General
1
Analgesia, Patient-Controlled
1
Acupuncture Therapy
1
Acceptance and Commitment Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Agnosia
×
Ketamine
×
Clear all
NCT00210210
2025-09-19
KETAMINE
Institut Bergonié
Phase 3
Completed
230 enrolled
6 charts